The non-glycemic effects of incretin therapies on cardiovascular outcomes, cognitive function and bone health. Issue 1 (January 2015)

• Record Type: Journal Article
• Authors: Hanna, Amir; Connelly, Kim A; Josse, Robert G; McIntyre, Roger S
• Is Part Of: Expert review of endocrinology & metabolism. Volume 10:Issue 1(2015)
• Page Start: 101
• Page End: 114
• Publication Date: 2015-01
• Subjects: Endocrinology -- Periodicals; Metabolism -- Periodicals; 616.4
• DOI: 10.1586/17446651.2015.972370
• Languages: English
• ISSNs: 1744-6651

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p>The incretin therapies, glucagon-like peptide-1 receptor agonists and dipeptidyl-peptidase-4 inhibitors, have been developed to lower blood glucose levels in patients with Type 2 diabetes. However, in addition to being a treatment strategy to improve metabolic control, incretin therapies have shown effects independent of glycemic control, including the potential to positively impact cardiovascular events, cognitive deficits and bone mineral density. This paper outlines the non-glycemic effects of incretin therapies on cardiovascular disease, cognitive function and bone health.</p> </abstract>